Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | CCKAR | P32238 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870573 | 0.85 | ALDH1A1 (0.44) | NPC1MAPTGAAMAPK1ALDH1A1 | |
| SCHEMBL4865528 | 0.84 | MEN1 (0.47) | NPC1MAPTGAAALDH1A1LMNA | |
| SCHEMBL4866408 | 0.84 | ALDH1A1 (0.48) | NPC1MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL4871242 | 0.81 | PTGS1 (0.42) | GAAALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL4866921 | 0.79 | L3MBTL1 (0.43) | NPC1MAPTGAAMAPK1ALDH1A1 | |
| SCHEMBL4870542 | 0.77 | LMNA (0.42) | NPC1MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL4866826 | 0.76 | MAPT (0.42) | NPC1MAPTGAAMAPK1ALDH1A1 | |
| SCHEMBL4873322 | 0.75 | SMN1; SMN2 (0.43) | NPC1MAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL4876301 | 0.75 | KMT2A (0.47) | NPC1MAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4866793 | 0.75 | KMT2A (0.44) | MAPTALDH1A1L3MBTL1ACHEALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | claimed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | claimed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | claimed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | NPC1 1292/4885MAPT 2762/4885GAA 652/4885 |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | NPC1 1163/4885MAPT 2821/4885GAA 654/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | NPC1 1292/4885MAPT 2762/4885GAA 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.